Literature DB >> 2540787

Small cell lung cancer.

R C Leonard1.   

Abstract

Entities:  

Mesh：

Year:  1989        PMID： 2540787      PMCID： PMC2247163          DOI： 10.1038/bjc.1989.101

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  19 in total

1.  Late intensification in small-cell lung cancer: a phase I study of high doses of cyclophosphamide and etoposide with autologous bone marrow transplantation.

Authors:  J P Sculier; J Klastersky; P Stryckmans
Journal:  J Clin Oncol       Date:  1985-02       Impact factor: 44.544

2.  Small-cell lung cancer--whither late intensification?

Authors:  R B Livingston
Journal:  J Clin Oncol       Date:  1986-10       Impact factor: 44.544

3.  Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer.

Authors:  D C Ihde; A B Deisseroth; A S Lichter; P A Bunn; D N Carney; M H Cohen; S R Veach; R W Makuch; A Johnston-Early; R A Abrams
Journal:  J Clin Oncol       Date:  1986-10       Impact factor: 44.544

4.  High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma.

Authors:  I E Smith; B D Evans; S J Harland; B A Robinson; J R Yarnold; J G Glees; H T Ford
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody.

Authors:  R A Stahel; M Mabry; A T Skarin; J Speak; S D Bernal
Journal:  J Clin Oncol       Date:  1985-04       Impact factor: 44.544

6.  Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies.

Authors:  S Fargion; D Carney; J Mulshine; S Rosen; P Bunn; P Jewett; F Cuttitta; A Gazdar; J Minna
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

7.  The influence of myelosuppression on the response to chemotherapy in small cell bronchogenic carcinoma.

Authors:  P Y Holoye; J Kalbfleisch
Journal:  Cancer       Date:  1984-08-01       Impact factor: 6.860

8.  Cisplatin, adriamycin, and etoposide (CAV) for remission induction of small-cell bronchogenic carcinoma.

Authors:  J Klastersky; C Nicaise; E Longeval; P Stryckmans
Journal:  Cancer       Date:  1982-08-15       Impact factor: 6.860

9.  The hospital anxiety and depression scale.

Authors:  A S Zigmond; R P Snaith
Journal:  Acta Psychiatr Scand       Date:  1983-06       Impact factor: 6.392

10.  High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lung.

Authors:  D Cunningham; S W Banham; A H Hutcheon; A Dorward; S Ahmedzai; P Tansey; M Soukop; R D Stevenson; B R Stack; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333
View more
  4 in total

1.  Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy carboplatin, etoposide, and epirubicin.

Authors:  P Collard; P Weynants; C Francis; D O Rodenstein
Journal:  Thorax       Date:  1992-05       Impact factor: 9.139

2.  Is the progress in cancer treatment results adequate or are we confronted with a more or less worldwide stagnation.

Authors:  K Karrer
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

3.  Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma.

Authors:  C M Kirsch; J von Pawel; I Grau; K Tatsch
Journal:  Eur J Nucl Med       Date:  1994-12

4.  A Medical Research Council phase II trial of alternating chemotherapy and radiotherapy in small-cell lung cancer. The Medical Research Council Lung Cancer Working Party.

Authors:  N M Bleehen; D J Girling; A Gregor; R C Leonard; D Machin; C G McKenzie; D A Morgan; J F Smyth; M F Spittle; R J Stephens
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.